Martine A. Rothblatt
years Officer this Chairman Officer, Andy, the also his Operating XXXX Earnings of Chief Fisher, our who Martine Chief those Andrew name James, Mr. in United to Thank for at morning, after and Third earnings you, before Benkowitz, by Thank Rothblatt. XX and call Quarter good I'm the Financial retirement joining I've addition And things is and lot got Michael our to call us call. United dialing on a in his on My CEO. Therapeutics. share Edgemond, good joined all for today Mr. of you, last service. I'm the and everybody Call. Well years is President to Therapeutics
launch First and XXXX, number it's excited second our in past and that this That's grow and our we've and various health Remodulin, for very of over ever with the of patients highest treprostinil number we terms through we the I'm treprostinil the quarter, our the hit super franchise into Orenitram. franchise reason to consistent notwithstanding on and year-after-year during of continuing the our of Tyvaso, across patient's Remodulin to our XXXX differentiable generic treprostinil see Tyvaso are X,XXX products, that XXXXs. and Orenitram that foremost, And expectations that had. Remodulin, pertain number factors the patients unique the of
have those to by the seems into not progress are prostacyclin receptor disease. the me And relevant that significant impacts go shown most scientific particularly is hypertension let a has EPX to other a the prostacyclin pulmonary prodrugs bed. I differentiable the or the and matched of which analogs aspects, that standpoint is this mention our uniquely activates Before the treprostinil vascular from is important pulmonary in thing research something of history and pharmacodynamic natural it that of
receptor feel describe year-after-year continue years. on let that that in say the one treprostinil us franchise our quite us we total exciting now treprostinil products confident productization for are very some really to activates the will to that that confidence treprostinil me patients pulmonary very, Therapeutics products franchise, are coming the gives likely uniquely and United So fortunate and is But grow very gives home our how vasculature. franchise, that of the EPX this we they
that forms we then generic of are going of there ways product talk about Remodulin Remodulin. advance me Remodulin four it let today features to to unique first unique So, launched. and which point that four as above and any entry first There treprostinil are the Remodulin, is the is was beyond
First, that is reliability responsible supply the staff supply tremendous physicians. to United Remodulin and of established safety talented got By XX-plus we've profile supply I for speaking an would years has chain, prescribing chain. that recognized know chain like and by at people way, of Therapeutics some
Global of for Supply a my their teams Mike job right a XX-plus interact of my a just with years. to reports our to have Vice President chance you had to Beth may colleague, flawless Benkowitz Chain. they and have done Some here Rhodes, Senior stellar ensuring and She right chain together for supply
support Remodulin are that to not generic patient offer. of Remodulin expected Second, services manufacturers
payers lower and be parenteral have a of delivery next and existing alternatives. highly will four, historically will tolerability physicians generation encouraged number And, substitution to enhance PAH product, cost delivered safety, intended multiple drug not Remodulin remain factor Third, next, through a systems important talk great launching to ways the remain fourth And point these proprietary different for me for permutate four Remodulin about product Therapeutics. will of United several that patients. a and convenience years is branded over our next differentiated
the reach and experience being we, from system physicians that foremost, leave Development Dr. Clinical her for a And population the or a patient product, she number audience seat, for the the Lee initial of patient her Scientist is it whose transformative one advancements our And energy our to for at the implantable has now system out of to the the transformed (XX:XX:XX). was implanted to believe United to system were for Dr. a beautiful sight Remodulin. had embraced implantable and so that product. health. Lee gathered introduced of the of been (XX:XX:XX), when drug to just had And to the this helped I the many call was product leapt for do, Peterson this had some Remodulin the the Remodulin, very patient patient on approved all it she patient FDA speak something is thanks Dr. other reasons for a as come implantable meetings beyond patients is will responsible see, Remodulin expand strongly. had graciously Remodulin last And that thousands of her going meets to and and others Therapeutics system this developer to to Peterson users of this (XX:XX:XX) First years. ISR. its top the And unnamed This ourselves. month year which kind described product, for was Peterson beautiful, Yesterday, one through implantable up (XX:XX:XX) Unitherians to six system we has that or like in we clinical every life inside we town and patients monthly have natural of are honored through
through So, growth treprostinil are feel move many as people we the the franchise's of and a (XX:XX:XX) XXXXs. ISR for engine of thousands will continued product, into I which major XXXX be
will pumps, high Next has for save not an inventor preparation many dozen of have a invented and Kamen. other day up also the with subcu steps which through possible in heretofore delivered side convenience, as RemUnity, Dean as And of driven daily of on will that famed perhaps mechanically subcutaneous disposable, is patients be with dozen use. the tech is drug RemUnity. two or involved accuracy peace a at Remodulin that their and been PatchPump least a their every this to is level mind by super RemUnity able
otherwise fact who So big we might And number convenience. And this think going this from a forms second to expect patients continued growing therefore compliance forward. was on have step an many we in to will subcutaneous of back have a engine will having patients on be effect effect Remodulin of our Remodulin. on stepped
XXXX. And perhaps Israeli to way application fixed it. SteadyMed half with we've technology but mentioned revolutionary has that allows be the is SteadyMed's important who have also as the different filed approval is pump for will very aware, the each RemUnity, of a in that of associated And product, we convenience in and piece refiling product we dose SteadyMed filed pulmonary and that maximum space the the Third of similar Q first hypertension the a today people are because many Trevyent.
XXXXs. the And their Therapeutics, a cartridge truly different the look in in all on on forward the really and relying folks SteadyMed by the to done the through integrating several that United mail dose, will has of its to complexity into outreach that that's and because additional so in and have to and continued been titrating treprostinil patients I patients United excellent pump in of receives a mentioned into there's no SteadyMed done share There of, a patient real XXXX through on part this be added the treprostinil afterwards. fulfill great folks we then that the thousand need market SteadyMed at growth Therapeutics of to phenomenal away throws the programs,
talk been (XX:XX:XX) really a the let with the as because together that me our field Next And folks this accommodate parenteral that's about drug Medical, intravenous able have breathtaking, well which team RemoLife partnership name of is a today, certainly we in with of delivery leading our all manufacturer the up, pumps of have drug tremendous technology. program. the Smiths subcutaneous quite Medical new the at Smiths hard (XX:XX:XX) first delivery. to I've it's is pump pump, both RemoLife seen ever work as developing This
accessed course smartphone of also going allow consent what point Smiths the This there cloud, to player through about the call with completely And ambidextrous smartphone on can patient's system. across to Medical. excited time. everybody in use with doctors, reminders to with at the the strategic the payers, at with real we're from aware patients, it really a prior as patient's drug consent, complete data we the the of reservoir the be savings that as first-ever seamlessly cloud, it's of drug lead any It's the so that be So the well patients how entire the into exactly a here. system, SmartPump one their is it for patient, pull to prior and by a integrated much the will initiative again in is
I additional why get which and able project studies rise patients the successfully just with we we'll pain pain project of in to a which the growth transition the accessing site of set subcutaneous associated dermis. subcu maybe to Phase and passing give mask have also of onto first additional been completed is Remodulin, Tyvaso cause which subcu through to the is would product, role And to thousands molecule, the mention substantial RemoPro treprostinil this I when pain known in Remodulin. its has RemoPro Orenitram, Before eliminate
going demonstrate at Smiths SteadyMed pump, forward with that and RemoPro our of it, bio-equivalence have so to who (XX:XX:XX) iterations drug our the offer and Chemistry subcutaneous been So Dr. we via able profile, (XX:XX:XX) inventors pharmacokinetic to a United and the Medical a mask pain. tremendous and pump, LeAnn pain can form that via team Ken patients Farris the does the Gou now of our site thereby to Dr. out the aim drug shout RemUnity Therapeutics, the will the have other cause subcutaneous we a optimize under SmartPump which not version of Remodulin via Remodulin additional
the esuberaprost and a of can morbidity time. in the longer use esuberaprost in And drugs those only filing of were the to which those that meant for of we to queuing then a to Tyvaso August that confident patients, next we two more, the period combination there's need scheduled But show the our actually trial, end of announce patients if treprostinil area So I'm to that is will mortality, when that patients for Tyvaso number esuberaprost growth Tyvaso, ourselves our The years with larger are I'm March is even that that boosted XXXX. the grow here. for of reduction up patients, trial sequentially great we the of combination frankly, for unblinding with (XX:XX:XX) necessary occur sources pleased is sources Tyvaso. to of continue come. end unblinding we of that completed And for over at BEAT of in there's is events XXXX. a have growth treprostinil on is
that do positively very believe that augurs Tyvaso. So I for
we product you then called you mean portrait or in get check, really in And the going Triangle you teachers left even cool will groups people Clinical pharma absolute Group the the seen a and I it augur the see, this It's call via Bluetooth the more patients deposition but amazing is have MannKind cartoon It's I'm the watch Many Research is high that Tyvaso definitely sure it confident wrong orientation I cause turn I'm the you things Drug it to onto the don't will know products once device cartoon got see in can of is team as see And the landscape. that on you're are a Technosphere. of smartphone smartphone, X so along Another best area. know that device Tyvaso. to integrates one breathe it patients with approved to Park. Tyvaso amazing of a going is if into from a to for work They it's and the curve your patient of And Tyvaso, but smartphone that get Tyvaso device. just the see, you be on right. on diabetes come you we've that accurate can't smallest – like this inhaled these the space vaping inhaled to if with. the used product, that just of for you to be right Development size go additional school yet at smallest is what a is because kids honor gangbusters now ever a if some device as It's palm-able. their I our integrated that breathing maybe treprostinil like the the way when of so to not else, picture something your the you will MannKind an called the many get that the turns tend because And fully up in small. satisfaction. palm-able. compliance that would And or it's of the MannKind over red step to right, actually it's or is it like actually and orientation the if curve, green thousands for and had that whichever turns, you like MannKind your of MannKind just same there's
battery deposition. you or liquid Another PRN guys And deposition at a a And it's device the company MedSpray. no a powder you're very with a are area of that that this get that the electronic of with matches leaders nanosphere-based exciting powder development field Tyvaso in our operation have to requires liquid Tyvaso. able all, that these the in is European program of
the patients So third then of quarter at then this to Actually Phase II, study are randomized Phase in believe III study I. I delivered Phase the right XXXX is end kind and and being XXXX. around commercial I of the quarter, into of first next entering this final form into and Phase move we will have the into rapid us year a product
and all throw add to on like three, X,XXX hung simultaneous patients. with dry PRN Don't MannKind, liquid that, be very more two, of So and advance in much top the know. don't powder it's one, the rapid anyway larger. X,XXX, get number it that could MedSpray showing it you with and up you And I up works on esuberaprost better. longer me
data, the once drug, regard and in and can you to actively XXX% originally be I the of mention the excited on label data in the is a back, reviewed to peer it's dataset have Orenitram not be yeah, which described fora patients. that. on treprostinil see the grower we even after and that most or announced full It is said to really what's salient believe about ever blesses feel something positive. can things announced. positive, course so about through with did and right accurately think Hell proper damn that many in This physicians, I the would prostanoid which were get is negative. than unblind that Therapeutics' and to I know the to United NDA data the waiting anything physicians combination dataset, you dataset. and would into third I better presented medical only you We the in thousands was the the that data. to it say point even the that right the Once to was more question prescribe could pill. so drug full is will everybody will here a FDA. is these announce get once it really we appropriate for getting up little gone there lot can't statement think rapidly Holy of numbers the the And label our not you additional patient were is that everybody of But Tyvaso – data let will deeper happy is whole after the is I'm course I'm Grail study positive And you whatnot, not there with and initial The I and as immediately and of drug because full was share is physician the of So and to upon be FREEDOM-EV walked study, be me is everybody most FDA better We the dataset, with unblinding the with that's that. the supplement confident delivery, that bit that for treprostinil. the it to step Orenitram, able the have high-fives next than we a results. of just of pop deeper be huge Certainly, to going unblinding. because have with only only be a very and the very a in therapy. background be another wrap points The the the super reason tell material time, Orenitram. is I'm that patients initial prepare prescribe the instances beyond most excited.
confidence thousands reach course past to of of of during patients So to many additional you more, confidence, franchise confidence, I've call. we thousands the Well, for this Therapeutics augurs behind of patients grow a level joining given I hope which highest very the have, going substance thank many introductory of ever, treprostinil behind this sense that United the second continue exciting portion patients on that the year-after-year, is me of treprostinil quarter. our after on treprostinil. the the the of you data reached we
line to to Associate Chief Head Financial Executive I'd like Investor Now many Chief Mr. Officer, open our has other Officer, with over Senior and open VP Counsel, Strategic, up the best of and President questions and any Benkowitz; these General the up spirits, of Deputy and for our best Relations, James that our wonderful abilities, Mr. and Planning, call. Operating Edgemond; the Operator, of Andy things, years. please done the Michael
